Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody JS016 in Hospitalized Chinese Patients with COVID-19: a Phase 2/3, Multicenter, Randomized, Open-Label, Controlled Trial
Dong et al., Antimicrobial Agents and Chemotherapy, doi:10.1128/aac.02045-21
https://c19early.org/dong4.html